

AMENDMENT

In the claims:

Please amend the claims as follows:

1-16. Canceled

17. (Presently amended) A method of inducing a mean ELISA antibody titer of about 1×10^2 mg/ml or more against ricin toxin ~~or more~~ in a subject comprising administering to the subject an amount of a chemically deglycosylated ricin A-chain.

18. (Presently amended) The method of claim 1, wherein the deglycosylated ricin-A chain is chemically deglycosylated by treating a ricin A-chain with a mixture of sodium metaperiodate and sodium cyanoborohydride at a pH 3.5 for 1 hour at 4 °C.

19. (Presently amended) The method of claim ~~4~~ 18, wherein the deglycosylated ricin A-chain is incompletely deglycosylated.

20. (Presently amended) The method of claim 19, wherein ~~mannose and fructose are absent from the deglycosylated ricin A-chain~~ the deglycosylated ricin A-chain contains about 50% of mannose residues present in wild-type ricin toxin.

21. (Original) The method of claim 17, wherein the amount is an immunogenic amount.

22. (Presently amended) The method of claim 21, wherein the immunogenic amount is about ~~0.1 µg to about 10.0 µg per about 20 g to about 25 g~~ 0.01 µg to about 100 µg per kg of the weight of the subject.

23. (Previously amended) The method of claim 17, wherein two doses of the deglycosylated ricin A-chain are administered to the subject.

24. (Original) The method of claim 17, further comprising administering an adjuvant to the subject.

25. (Original) A method for providing neutralizing antibodies against ricin toxin or preventing ricin intoxication in a subject comprising administering at least two doses of an immunogenic amount of a chemically deglycosylated ricin A-chain to the subject.

26. (Original) The method of claim 25, wherein the chemically deglycosylated ricin A-chain is incompletely deglycosylated.

27. (Original) The method of claim 26, wherein mannose and fructose are absent from the chemically deglycosylated ricin A-chain.

28-39. Canceled

40. (Presently amended) The method of claim 17, wherein the amount of deglycosylated ricin A-chain is administered in the form of a vaccine, an immunogenic composition, or a pharmaceutical composition.

41. (Previously presented) The method of claim 40, wherein the deglycosylated ricin A-chain is incompletely deglycosylated.

42. (Previously presented) The method of claim 40, wherein the deglycosylated ricin A-chain is chemically deglycosylated.

43. (Presently amended) The method of claim 40, wherein ~~mannose and fructose are absent from the deglycosylated ricin A-chain~~ the deglycosylated ricin A-chain contains about 50% of mannose residues present in wild-type ricin toxin.

44. (Previously presented) The method of claim 40, wherein two doses of the vaccine, the immunogenic composition or the pharmaceutical composition provides neutralizing antibodies in a subject.

45. (Previously presented) The method of claim 40, wherein two doses of the vaccine, the immunogenic composition or the pharmaceutical composition prevents ricin intoxication in a subject.

46. (Previously presented) The method of claim 40, wherein the vaccine, the immunogenic composition or the pharmaceutical composition further comprises an adjuvant.